無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪肝炎 (NASH) の世界市場 (〜2027年):GFT 505・オベチコール酸 (INT-747)・Simtuzumab・リラグルチド (Victoza)・ビタミンE・ピオグリタゾン・プラセボ

Nonalcoholic Steatohepatitis (NASH) Market Report to 2027: Forecasts and Analysis by Therapeutics (GFT 505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region

発行 Visiongain Ltd 商品コード 603184
出版日 ページ情報 英文 145 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.14円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
非アルコール性脂肪肝炎 (NASH) の世界市場 (〜2027年):GFT 505・オベチコール酸 (INT-747)・Simtuzumab・リラグルチド (Victoza)・ビタミンE・ピオグリタゾン・プラセボ Nonalcoholic Steatohepatitis (NASH) Market Report to 2027: Forecasts and Analysis by Therapeutics (GFT 505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region
出版日: 2017年12月01日 ページ情報: 英文 145 Pages
概要

当レポートでは、世界の非アルコール性脂肪肝炎 (NASH) の市場を調査し、市場および疾患の定義と概要、薬剤・地域/主要国別の動向と市場規模の推移と予測、市場成長への影響因子および市場機会の分析、主要企業のプロファイルなどをまとめています。

第1章 レポート概要

第2章 イントロダクション

第3章 NASH市場の予測

第4章 NASH市場の予測:薬剤別

  • 概要
  • GFT 505
    • 競合シナリオ
  • オベチコール酸 (INT-747)
    • 競合シナリオ
  • Simtuzumab・リラグルチド (Victoza)
    • 競合シナリオ
  • ビタミンE
    • 競合シナリオ
  • ピオグリタゾン
    • 競合シナリオ
  • プラセボ

第5章 市場分析・予測:地域別

  • 地域市場の推移と予測
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • パラグアイ
    • ボリビア
    • その他
  • 欧州
    • フランス
    • ドイツ
    • 英国
    • スぺイン
    • イタリア
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • タイ
    • その他
  • その他の地域
    • 中東
    • アフリカ
    • その他

第6章 定性分析

  • ポーターのファイブフォース分析
  • 市場力学
  • 成長推進因子
  • 成長抑制因子
  • 市場機会

第7章 主要企業

  • AstraZeneca Plc
  • Intercept Pharmaceuticals, Inc.
  • GENFIT SA
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Bristol-Myers Squibb
  • Galmed Pharmaceuticals Ltd.
  • Immuron Limited
  • Novo Nordisk AG
  • その他

第8章 総論

第9章 用語

目次
Product Code: PHA0263

Report Details

  • Do you need definitive NASH market data?
  • Succinct NASH market analysis?
  • Technological insight?
  • Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

The increase in prevalence of hepatic pathology and its pathophysiology have propelled the growth of the novel therapeutic studies, which has given birth to the novel therapeutic solutions such as Farnesoid X Receptor (FXR) agonists, incretins and probiotics. Most of these studies are in last phase of their clinical trials and commercialization is expected within a short period of time that could be used in treating patients with NASH.

Report highlights

132 quantitative tables, charts, and graphs across 145 pages

Global NASH market outlook and analysis from to 2027

Global NASH submarket forecasts and analysis from to 2027

  • GFT 505
  • Obeticholic Acid (INT-747)
  • Simtuzumab and Liraglutide (Victoza)
  • Vitamin E
  • Pioglitazone
  • Placebo

Regional and National NASH market forecasts to 2027

  • North America forecast to 2027:
  • US forecast to 2027
  • Canada forecast to 2027
  • Mexico forecast to 2027
  • South America forecast to 2027:
  • Brazil forecast to 2027
  • Argentina forecast to 2027
  • Paraguay forecast to 2027
  • Bolivia forecast to 2027
  • Rest of South America forecast to 2027
  • Europe forecast to 2027:
  • Germany forecast to 2027
  • UK forecast to 2027
  • France forecast to 2027
  • Italy forecast to 2027
  • Spain forecast to 2027
  • Rest of Europe forecast to 2027
  • Asia-Pacific forecast to 2027
  • Japan forecast to 2027
  • India forecast to 2027
  • China forecast to 2027
  • Australia forecast to 2027
  • Thailand forecast to 2027
  • Rest of Asia-Pacific forecast to 2027
  • Rest of World forecast to 2027:
  • Middle East forecast to 2027
  • Africa forecast to 2027
  • Other Countries forecast to 2027

Key questions answered:

  • What does the future hold for the Pharmaceutical industry with regards to Nonalcoholic Steatohepatitis (NASH)
  • Where should you target your business strategy?
  • Which applications should you focus upon?
  • Which disruptive technologies should you invest in?
  • Which companies should you form strategic alliances with?
  • Which company is likely to success and why?
  • What business models should you adopt?
  • What industry trends should you be aware of?

Target audience

  • Leading Pharmaceutical companies
  • Suppliers
  • Contractors
  • Technologists
  • R&D staff
  • Consultants
  • Analysts
  • CEO's
  • CIO's
  • COO's
  • Business development managers
  • Investors
  • Governments
  • Agencies
  • Banks

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. NASH Market Overview
  • 1.2. Research Methodology
  • 1.3. Primary Research
  • 1.4. Secondary Research
  • 1.5. Market Evaluation & Forecasting Methodology
  • 1.6. Global NASH Market Segmentation
  • 1.7. Overview of Findings
  • 1.8. Why You Should Read This Report
  • 1.9. How this report delivers
  • 1.10. Key Questions Answered by this Analytical Report
  • 1.11. Frequently Asked Questions (FAQ)
  • 1.12. Who is This Report For?
  • 1.13. Associated Visiongain Reports
  • 1.14. About Visiongain

2. Introduction to NASH Market

  • 2.1. Dos and Don'ts for NASH
  • 2.2. Alcohol Intake
  • 2.3. Use of Statin
  • 2.4. Use of Hepatotoxic Drugs
  • 2.5. Vaccination for Hepatitis A and B

3. NASH Market Forecast to 2027

4. NASH Market by Therapeutics: Market Forecast to 2027

  • 4.1. Overview
  • 4.2. GFT 505
    • 4.2.1. Competitive Scenario
  • 4.3. Obeticholic Acid (INT-747)
    • 4.3.1. Competitive Scenario
  • 4.4. Simtuzumab and Liraglutide (Victoza)
    • 4.5.1. Competitive scenario
  • 4.5. Vitamin E
    • 4.5.1. Competitive Scenario
  • 4.6. Pioglitazone
    • 4.6.1. Competitive Scenario
  • 4.7. Placebo

5. Regional NASH Market Forecasts to 2027

  • 5.1. Regional NASH Market Forecast 2017-2027
  • 5.2. North American NASH Market Forecast 2017-2027
    • 5.2.1. USA NASH Market Forecast 2017-2027
    • 5.2.2. Canada NASH Market Forecast 2017-2027
    • 5.2.3. Mexico NASH Market Forecast 2017-2027
  • 5.3. South American NASH Market Forecast 2017-2027
    • 5.3.1. Brazil NASH Market Forecast 2017-2027
    • 5.3.2. Argentina NASH Market Forecast 2017-2027
    • 5.3.3. Paraguay NASH Market Forecast 2017-2027
    • 5.3.4. Bolivia NASH Market Forecast 2017-2027
    • 5.3.5. Rest of South America NASH Market Forecast 2017-2027
  • 5.4. European NASH Market Forecast 2017-2027
    • 5.4.1. France NASH Market Forecast 2017-2027
    • 5.4.2. Germany NASH Market Forecast 2017-2027
    • 5.4.3. UK NASH Market Forecast 2017-2027
    • 5.4.4. Spain NASH Market Forecast 2017-2027
    • 5.4.5. Italy NASH Market Forecast 2017-2027
    • 5.4.6. Rest of Europe NASH Market Forecast 2017-2027
  • 5.5. Asia-Pacific NASH Market Forecast 2017-2027
    • 5.5.1. China NASH Market Forecast 2017-2027
    • 5.5.2. Japan NASH Market Forecast 2017-2027
    • 5.5.3. India NASH Market Forecast 2017-2027
    • 5.5.4. Australia NASH Market Forecast 2017-2027
    • 5.5.5. Thailand NASH Market Forecast 2017-2027
    • 5.5.6. Rest of Asia-Pacific NASH Market Forecast 2017-2027
  • 5.6. Rest of World NASH Market Forecast 2017-2027
    • 5.6.1. Middle East NASH Market Forecast 2017-2027
    • 5.6.2. Africa NASH Market Forecast 2017-2027
    • 5.6.3. Other Countries NASH Market Forecast 2017-2027

6. NASH Market, Qualitative Analysis, 2017-2027

  • 6.1. Porter's Five Forces Analysis of the NASH Market
    • 6.1.1. Bargaining Power of Buyers (Low)
    • 6.1.2. Bargaining Power of Suppliers (Medium)
    • 6.1.3. Threat of New Entrants (Low)
    • 6.1.4. Threat of Substitute Products (Medium)
    • 6.1.5. Intensity of Competitive Rivalry (Low)
  • 6.2. Market Dynamics
  • 6.3. Drivers
    • 6.3.1. Rampant Growth Rate Of Obesity And Diabetes Globally
    • 6.3.2. Acceleration in Initiatives For Research And Development Activities
  • 6.4. Restraints
    • 6.4.1. Slower Development Of Therapeutics for NASH
    • 6.4.2. Blurred Understanding of Pathophysiology of NASH
    • 6.4.3. Inefficient Diagnostic Technology for NASH
  • 6.5. Opportunities
    • 6.5.1. Biomarker technologies in diagnosis of NASH

7. Leading Companies in NASH Market

  • 7.1. AstraZeneca Plc
    • 7.1.1. AstraZeneca Plc: Company Overview
    • 7.1.2. AstraZeneca Plc: Product Portfolio
  • 7.2. Intercept Pharmaceuticals, Inc.
    • 7.2.1. Intercept Pharmaceuticals, Inc.: Company Overview
    • 7.2.2. Intercept Pharmaceuticals, Inc.: Recent Developments
  • 7.3. GENFIT SA
    • 7.3.1. GENFIT SA: Company Overview
    • 7.3.2. GENFIT SA: Product Portfolio
  • 7.4. Gilead Sciences, Inc.
    • 7.4.1. Gilead Sciences, Inc.: Company Overview
    • 7.4.2. Gilead Sciences, Inc.: Product Portfolio
    • 7.4.3. Gilead Sciences, Inc.: Recent Developments
  • 7.5. Merck & Co. Inc.
    • 7.5.1. Merck & Co. Inc.: Company Overview
    • 7.5.2. Merck & Co. Inc.: Product Portfolio
    • 7.5.3. Merck & Co. Inc.: Recent Developments
  • 7.6. Novartis AG
    • 7.6.1. Novartis AG: Company Overview
    • 7.6.2. Novartis AG: Product Portfolio
    • 7.6.3. Novartis AG: Recent Developments
  • 7.7. Bristol-Myers Squibb
    • 7.7.1. Bristol-Myers Squibb: Company Overview
    • 7.7.2. Bristol-Myers Squibb: Product Portfolio
  • 7.8. Galmed Pharmaceuticals Ltd.
    • 7.8.1. Galmed Pharmaceuticals Ltd.: Company Overview
    • 7.8.2. Galmed Pharmaceuticals Ltd.: Recent Developments
  • 7.9. Immuron Limited
    • 7.9.1. Immuron Limited: Company Overview
  • 7.10. Novo Nordisk AG
    • 7.10.1. Novo Nordisk AG: Company Overview
    • 7.10.2. Novo Nordisk AG: Product Portfolio
  • 7.11. Other Companies of Interest in the NASH Market

8. Conclusions

  • 8.1. Current Leading Segments
  • 8.2. Leading Regional Markets
  • 8.3. Emerging Markets
  • 8.4. The Future of the Market?

9. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 3.1: NASH Market, by Therapeutics, ($m), 2017-2027
  • Figure 4.1: NASH Market, by Therapeutics, Market Share (%), 2016
  • Figure 4.2: NASH Market, by Therapeutics, Forecast ($m) 2017-2027
  • Figure 4.3: Global GFT 505 for NASH Market Forecast, by Geography, ($m) 2017-2027
  • Figure 4.4: Global Obeticholic Acid (INT-747) for NASH Market Forecast, by Geography, ($m) 2017-2027
  • Figure 4.5: Global Simtuzumab and Liraglutide (Victoza) for NASH Market Forecast, by Geography, ($m) 2017-2027
  • Figure 4.6: Global Vitamin E for NASH Market Forecast, by Geography, ($m) 2017-2027
  • Figure 4.7: Global Pioglitazone for NASH Market Forecast, by Geography, ($m) 2017-2027
  • Figure 4.8: Global Placebo for NASH Market Forecast, by Geography, ($m) 2017-2027
  • Figure 5.1: Global NASH Market Forecast, by Geography, by Geography ($m) 2017-2027
  • Figure 5.2: Global NASH Market Forecast, by Geography, Market Share (%), 2016
  • Figure 5.3: North America NASH Market Forecast, by Country ($m) 2017-2027
  • Figure 5.4: North America NASH Market, by Country, Market Share (%), 2016
  • Figure 5.5: USA NASH Market Forecast ($m) 2017-2027
  • Figure 5.6: Canada NASH Market Forecast ($m) 2017-2027
  • Figure 5.7: Mexico NASH Market Forecast ($m) 2017-2027
  • Figure 5.8: South America NASH Market Forecast, by Country ($m) 2017-2027
  • Figure 5.9: South America NASH Market, by Country, Market Share (%), 2016
  • Figure 5.10: Brazil NASH Market Forecast ($m) 2017-2027
  • Figure 5.11: Argentina NASH Market Forecast ($m) 2017-2027
  • Figure 5.12: Paraguay NASH Market Forecast ($m) 2017-2027
  • Figure 5.13: Bolivia NASH Market Forecast ($m) 2017-2027
  • Figure 5.14: Rest of South America NASH Market Forecast ($m) 2017-2027
  • Figure 5.15: Europe NASH Market Forecast, by Country ($m) 2017-2027
  • Figure 5.16: Europe NASH Market, by Country, Market Share (%), 2016
  • Figure 5.17: France NASH Market Forecast ($m) 2017-2027
  • Figure 5.18: Germany NASH Market Forecast ($m) 2017-2027
  • Figure 5.19: UK NASH Market Forecast ($m) 2017-2027
  • Figure 5.20: Spain NASH Market Forecast ($m) 2017-2027
  • Figure 5.21: Italy NASH Market Forecast ($m) 2017-2027
  • Figure 5.22: Rest of Europe NASH Market Forecast ($m) 2017-2027
  • Figure 5.23: Asia-Pacific NASH Market Forecast, by Country ($m) 2017-2027
  • Figure 5.24: Asia-Pacific NASH Market, Market Share (%), 2016
  • Figure 5.25: China NASH Market Forecast ($m) 2017-2027
  • Figure 5.26: Japan NASH Market Forecast ($m) 2017-2027
  • Figure 5.27: India NASH Market Forecast ($m) 2017-2027
  • Figure 5.28: Australia NASH Market Forecast ($m) 2017-2027
  • Figure 5.29: Thailand NASH Market Forecast ($m) 2017-2027
  • Figure 5.30: Rest of Asia-Pacific NASH Market Forecast ($m) 2017-2027
  • Figure 5.31: RoW NASH Market Forecast, by Country ($m) 2017-2027
  • Figure 5.32: Rest of World NASH Market, by Country, Market Share (%), 2016
  • Figure 5.33: Middle East NASH Market Forecast ($m) 2017-2027
  • Figure 5.34: Africa NASH Market Forecast ($m) 2017-2027
  • Figure 5.35: Other Countries NASH Market Forecast ($m) 2017-2027
  • Figure 6.1: Porter's Five Forces Analysis of the NASH Market
  • Figure 6.2: Number of Incidences of Diabetes Globally, by Geography (2000, 2011 & 2030)
  • Figure 7.1: AstraZeneca Plc, Revenue, ($million), 2012-2016
  • Figure 7.2: AstraZeneca Plc, Product Segments Share (%), 2016
  • Figure 7.3: Intercept Pharmaceuticals, Inc., Revenue, ($million), 2012-2016
  • Figure 7.4: GENFIT SA, Revenue, ($million), 2012-2016
  • Figure 7.5: Gilead Sciences, Inc., Revenue, ($million), 2012-2016
  • Figure 7.6: Gilead Sciences, Inc., Product Segments Share (%), 2016
  • Figure 7.7: Gilead Sciences, Inc., Geographical Presence Share (%), 2016
  • Figure 7.8: Merck & Co. Inc., Revenue, ($million), 2012-2016
  • Figure 7.9: Merck & Co. Inc., Product Segments Share (%), 2016
  • Figure 7.10: Merck & Co. Inc., Geographical Presence Share (%), 2016
  • Figure 7.11: Novartis AG, Revenue, ($million), 2012-2016
  • Figure 7.12: Novartis AG, Product Segments Share (%), 2016
  • Figure 7.13: Novartis AG, Geographical Presence Share (%), 2016
  • Figure 7.14: Bristol-Myers Squibb, Revenue, ($million), 2012-2016
  • Figure 7.15: Bristol-Myers Squibb, Product Segments Share (%), 2016
  • Figure 7.16: Bristol-Myers Squibb, Geographical Presence Share (%), 2016
  • Figure 7.17: Novo Nordisk AG, Revenue, ($million), 2012-2016
  • Figure 8.1: World NASH, by Therapeutics, ($m), 2017-2027
  • Figure 8.2: World NASH, by Geography, ($m), 2017-2027

List of Tables

  • Table 3.1: NASH Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 4.1: NASH Market Forecast, by Therapeutics ($m, AGR%, CAGR%) 2017-2027
  • Table 4.2: Global GFT 505 for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.3: Global GFT 505 for NASH Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.4: Global Obeticholic Acid (INT-747) for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.5: Global Obeticholic Acid (INT-747) for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027
  • Table 4.6: Global Simtuzumab and Liraglutide (Victoza) for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.7: Global Simtuzumab and Liraglutide (Victoza) for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027
  • Table 4.8: Global Vitamin E for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.9: Global Vitamin E for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027
  • Table 4.10: List of Key Pioglitazone Brands Available in the Market
  • Table 4.11: Global Pioglitazone for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.12: Global Pioglitazone for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027
  • Table 4.13: Global Placebo for NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.14: Global Placebo for NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027
  • Table 5.1: NASH Market Forecast, by Geography ($m, AGR%, CAGR%) 2017-2027
  • Table 5.2: North America NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027
  • Table 5.3: USA NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.4: Canada NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.5: Mexico NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.6: South America NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027
  • Table 5.7: Brazil NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.8: Argentina NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.9: Paraguay NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.10: Bolivia NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.11: Rest of South America NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.12: European NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027
  • Table 5.13: France NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.14: Germany NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.15: UK NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.16: Spain NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.17: Italy NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.18: Rest of European NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.19: Asia-Pacific NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027
  • Table 5.20: China NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.21: Japan NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.22: India NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.23: Australia NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.24: Thailand NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.25: Rest of Asia-Pacific NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.26: Rest of World NASH Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027
  • Table 5.27: Middle East NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.28: Africa NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.29: Other Countries NASH Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 7.1: AstraZeneca Plc: Company Overview
  • Table 7.2: AstraZeneca Plc: Product Portfolio
  • Table 7.3: Intercept Pharmaceuticals, Inc.: Company Overview
  • Table 7.4: Intercept Pharmaceuticals, Inc.: Recent Developments
  • Table 7.5: GENFIT SA: Company Overview
  • Table 7.6: GENFIT SA: Product Portfolio
  • Table 7.7: Gilead Sciences, Inc.: Company Overview
  • Table 7.8: Gilead Sciences, Inc.: Product Portfolio
  • Table 7.9: Gilead Sciences, Inc.: Recent Developments
  • Table 7.10: Merck & Co. Inc.: Company Overview
  • Table 7.11: Merck & Co. Inc.: Product Portfolio
  • Table 7.12: Merck & Co. Inc.: Recent Developments
  • Table 7.13: Novartis AG: Company Overview
  • Table 7.14: Novartis AG: Product Portfolio
  • Table 7.15: Novartis AG: Recent Developments
  • Table 7.16: Bristol-Myers Squibb: Company Overview
  • Table 7.17: Bristol-Myers Squibb : Product Portfolio
  • Table 7.18: Galmed Pharmaceuticals Ltd.: Company Overview
  • Table 7.19: Galmed Pharmaceuticals Ltd.: Recent Developments
  • Table 7.20: Immuron Limited: Company Overview
  • Table 7.21: Novo Nordisk AG: Company Overview
  • Table 7.22: Novo Nordisk AG: Product Portfolio
  • Table 7.23: Other Companies of Interest in the NASH Market

Companies Listed

  • Abbott Laboratories
  • AbbVie, Inc.
  • Alkermes Plc
  • Amarin Corp. Plc
  • Amgen, Inc.
  • Amnis Corporation
  • Array BioPharma, Inc.
  • Associates Of Cape Cod Inc.
  • Astex Pharmaceuticals Inc.
  • AstraZeneca Plc
  • ASYMPTOTE LTD
  • Bayer AG
  • Bayer Corporation
  • Bayer HealthCare AG
  • Bayer Schering Pharma Aktiengesellschaft
  • BioLife Solutions, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Biotest AG
  • Bristol-Myers Squibb Co.
  • Cardax, Inc.
  • Cardinal Health, Inc.
  • Ceapro, Inc.
  • Celgene Corp.
  • Cephalon, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • CK Life Sciences International (Holdings), Inc.
  • Consensys Imaging Service Inc.
  • Cornerstone Research & Development Inc.
  • Crescendo Bioscience, Inc.
  • CTI BioPharma Corp.
  • Deroyal Industries Inc.
  • Domain Therapeutics SA
  • Emd Millipore Corporation
  • Emd Serono Inc.
  • Endo International Plc
  • Evotec AG
  • Galderma Sa
  • Galmed Pharmaceuticals Ltd.
  • GE HEALTHCARE LTD
  • Genfit SA
  • Gilead Sciences, Inc.
  • Henry Schein, Inc.
  • Illumina, Inc.
  • Immuron Limited
  • Intercept Pharmaceuticals, Inc.
  • Janssen Biotech, Inc.
  • JHL Biotech, Inc.
  • Johnson & Johnson
  • Laboratoire Theramex
  • Laboratory Corp. of America Holdings
  • LifeWatch AG
  • Lombard Medical, Inc.
  • Lonza Group AG
  • McKesson Corp.
  • Medline Industries Inc.
  • Medtronic Plc
  • Merck & Co., Inc.
  • Merck KGaA
  • MorphoSys AG
  • Motion Picture And Television Fund
  • Myrexis, Inc.
  • Myriad Genetics, Inc.
  • National Cancer Institute
  • NBTY, Inc.
  • Nexvet Biopharma PLC
  • Northwell Health Inc.
  • Novartis AG
  • Novartis AG
  • Novo Nordisk AG
  • Opexa Therapeutics, Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Owens & Minor, Inc.
  • Panacos Pharmaceuticals, Inc.
  • PELICAN HEALTHCARE LTD
  • Pfizer Inc.
  • Polymer Technology Systems Inc.
  • Progyny Inc.
  • Quanterix Corp.
  • Quest Diagnostics, Inc.
  • Smith & Nephew Plc
  • Vertex Pharmaceuticals, Inc.
  • Windtree Therapeutics, Inc.

List of Organizations:

  • China Food and Drug Administration
  • NHS
  • NICE
  • Stanford University
  • US Center for Disease Prevention and Control (CDC)
  • US Food and Drug Administration
  • World Bank
Back to Top